AI Portfolio Summary
In 2025 Q4, Affinity Asset Advisors, LLC maintained a portfolio of 125 distinct positions. The most significant new addition to the portfolio was SPDR SERIES TRUST, which now represents 10.42% of the total fund value. Conversely, Affinity Asset Advisors, LLC completely exited their position in VERONA PHARMA PLC.
Total Positions
125
Quarter
2025 Q4
Top Holding
XBI (10.4%)
Top 10 Concentration
43.1%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-25 of 125
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
XBI
PUT
SPDR SERIES TRU...
|
PUT Option | 10.42% | — |
#1
Prev: #—
|
6.2 | 1,500,000 | no change |
NEW
|
1,500,000 | $182,895,000 | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 5.31% | 4.06% |
#2
4
Prev: #6
|
4.1 | 61,500 | 5.2% |
P
S
|
1,234,926 | $93,212,214 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INSM
INSMED INC
|
Healthcare | 4.46% | 5.65% |
#3
1
Prev: #2
|
1.8 | no change | no change |
P
S
|
450,000 | $78,318,000 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABVX
ABIVAX SA
|
Healthcare | 3.88% | 2.66% |
#4
6
Prev: #10
|
3.7 | 145,000 | 40.3% |
P
S
|
505,000 | $68,101,775 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IBB
CALL
ISHARES TR
|
CALL Option | 3.85% | — |
#5
Prev: #—
|
3.5 | 400,000 | no change |
NEW
|
400,000 | $67,508,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VTYX
VENTYX BIOSCIEN...
|
Healthcare | 3.34% | 1.06% |
#6
24
Prev: #30
|
3.5 | 2,560,143 | 65.2% |
P
S
|
6,484,558 | $58,555,559 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 3.19% | 4.90% |
#7
3
Prev: #4
|
1.3 | -150,000 | -10.7% |
P
S
|
1,250,000 | $56,025,000 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 3.11% | — |
#8
Prev: #—
|
3.2 | 185,000 | no change |
NEW
|
185,000 | $54,526,900 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 2.90% | 1.68% |
#9
11
Prev: #20
|
3.5 | 450,000 | 128.6% |
P
S
|
800,000 | $50,832,000 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SYRE
SPYRE THERAPEUT...
|
Healthcare | 2.67% | 2.07% |
#10
8
Prev: #18
|
3.1 | 13,292 | 0.9% |
P
S
|
1,432,591 | $46,931,681 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
WVE
WAVE LIFE SCIEN...
|
Healthcare | 2.62% | 1.34% |
#11
12
Prev: #23
|
3.1 | 600,000 | 28.6% |
P
S
|
2,700,000 | $45,900,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMGN
CALL
AMGEN INC
|
CALL Option | 2.52% | — |
#12
Prev: #—
|
3.0 | 135,000 | no change |
NEW
|
135,000 | $44,186,850 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TEVA
TEVA PHARMACEUT...
|
Healthcare | 2.49% | 2.46% |
#13
Prev: #13
|
1.0 | no change | no change |
P
S
|
1,400,000 | $43,694,000 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XLV
CALL
SELECT SECTOR S...
|
CALL Option | 2.21% | — |
#14
Prev: #—
|
2.9 | 250,000 | no change |
NEW
|
250,000 | $38,700,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ROIV
ROIVANT SCIENCE...
|
Healthcare | 2.10% | 1.05% |
#15
16
Prev: #31
|
3.1 | 900,000 | 112.5% |
P
S
|
1,700,000 | $36,890,000 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACLX
ARCELLX INC
|
Healthcare | 1.95% | 3.58% |
#16
9
Prev: #7
|
2.8 | 23,725 | 4.7% |
P
S
|
523,725 | $34,146,870 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NUVL
NUVALENT INC
|
Healthcare | 1.85% | 2.90% |
#17
8
Prev: #9
|
0.8 | -61,784 | -16.1% |
P
S
|
322,633 | $32,453,653 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 1.81% | 2.24% |
#18
2
Prev: #16
|
0.8 | -670,527 | -17.3% |
P
S
|
3,200,000 | $31,776,000 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 1.59% | 3.27% |
#19
11
Prev: #8
|
0.7 | -250,000 | -20.0% |
P
S
|
1,000,000 | $27,980,000 | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
FBRX
FORTE BIOSCIENC...
|
Healthcare | 1.54% | — |
#20
Prev: #—
|
2.6 | 989,490 | no change |
NEW
|
989,490 | $26,983,392 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 1.53% | 2.23% |
#21
4
Prev: #17
|
0.7 | -649,828 | -23.2% |
P
S
|
2,150,172 | $26,920,153 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLYS
MINERALYS THERA...
|
Healthcare | 1.51% | 2.48% |
#22
10
Prev: #12
|
0.6 | -20,000 | -2.7% |
P
S
|
730,000 | $26,491,700 | 2023 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 1.39% | 0.29% |
#23
39
Prev: #62
|
2.9 | 255,000 | 392.3% |
P
S
|
320,000 | $24,476,800 | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORKA
ORUKA THERAPEUT...
|
Healthcare | 1.39% | 1.61% |
#24
3
Prev: #21
|
0.6 | -156,838 | -16.4% |
P
S
|
802,342 | $24,318,986 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 1.27% | — |
#25
Prev: #—
|
2.5 | 550,000 | no change |
NEW
|
550,000 | $22,220,000 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRNA
VERONA PHARMA P...
|
Unknown | 0.00% | 5.81% |
Sold All 😨
(Was: #1) |
0.3 | -625,000 | -100.0% |
CLOSED
|
— | $— | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SPY
SPDR S&P 500 ET...
|
ETF | 0.00% | 4.90% |
Sold All 😨
(Was: #3) |
0.3 | -84,490 | -100.0% |
CLOSED
|
— | $— | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INSM
CALL
INSMED INC
|
CALL Option | 0.00% | 2.57% |
Sold All 😨
(Was: #11) |
0.3 | -205,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MRUS
MERUS N V
|
Healthcare | 0.00% | 2.34% |
Sold All 😨
(Was: #14) |
0.3 | -285,769 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EXEL
PUT
EXELIXIS INC
|
PUT Option | 0.00% | 1.26% |
Sold All 😨
(Was: #25) |
0.3 | -350,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SLNO
SOLENO THERAPEU...
|
Healthcare | 0.00% | 1.18% |
Sold All 😨
(Was: #26) |
0.3 | -200,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
KARYOPHARM THER...
|
—
|
Bond/Debt | 0.00% | 1.09% |
Sold All 😨
(Was: #29) |
0.3 | -15,250,000 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
ELVN
ENLIVEN THERAPE...
|
Healthcare | 0.00% | 0.71% |
Sold All 😨
(Was: #38) |
0.3 | -400,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TARS
TARSUS PHARMACE...
|
Healthcare | 0.00% | 0.65% |
Sold All 😨
(Was: #43) |
0.3 | -125,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AKBA
AKEBIA THERAPEU...
|
Healthcare | 0.00% | 0.58% |
Sold All 😨
(Was: #45) |
0.3 | -2,450,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MNPR
MONOPAR THERAPE...
|
Healthcare | 0.00% | 0.57% |
Sold All 😨
(Was: #46) |
0.3 | -79,483 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EXEL
CALL
EXELIXIS INC
|
CALL Option | 0.00% | 0.54% |
Sold All 😨
(Was: #47) |
0.3 | -150,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NTLA
CALL
INTELLIA THERAP...
|
CALL Option | 0.00% | 0.45% |
Sold All 😨
(Was: #51) |
0.3 | -300,000 | -100.0% |
CLOSED
|
— | $— | 2021 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OMER
PUT
OMEROS CORP
|
PUT Option | 0.00% | 0.40% |
Sold All 😨
(Was: #55) |
0.3 | -1,133,900 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 0.00% | 0.39% |
Sold All 😨
(Was: #56) |
0.3 | -125,000 | -100.0% |
CLOSED
|
— | $— | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INSP
INSPIRE MED SYS...
|
Healthcare | 0.00% | 0.32% |
Sold All 😨
(Was: #60) |
0.3 | -50,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JAZZ
JAZZ PHARMACEUT...
|
Healthcare | 0.00% | 0.29% |
Sold All 😨
(Was: #63) |
0.3 | -25,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AUTL
AUTOLUS THERAPE...
|
Healthcare | 0.00% | 0.25% |
Sold All 😨
(Was: #66) |
0.3 | -1,750,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 0.00% | 0.24% |
Sold All 😨
(Was: #67) |
0.3 | -239,000 | -100.0% |
CLOSED
|
— | $— | 2020 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OLMA
CALL
OLEMA PHARMACEU...
|
CALL Option | 0.00% | 0.21% |
Sold All 😨
(Was: #71) |
0.3 | -250,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OLMA
OLEMA PHARMACEU...
|
Healthcare | 0.00% | 0.21% |
Sold All 😨
(Was: #70) |
0.3 | -250,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ATXS
ASTRIA THERAPEU...
|
Healthcare | 0.00% | 0.19% |
Sold All 😨
(Was: #73) |
0.3 | -300,000 | -100.0% |
CLOSED
|
— | $— | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
UTHR
UNITED THERAPEU...
|
Healthcare | 0.00% | 0.18% |
Sold All 😨
(Was: #74) |
0.3 | -5,000 | -100.0% |
CLOSED
|
— | $— | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ATYR
PUT
ATYR PHARMA INC
|
PUT Option | 0.00% | 0.13% |
Sold All 😨
(Was: #80) |
0.3 | -2,100,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MIST
MILESTONE PHARM...
|
Healthcare | 0.00% | 0.12% |
Sold All 😨
(Was: #81) |
0.3 | -666,666 | -100.0% |
CLOSED
|
— | $— | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
KPTI
CALL
KARYOPHARM THER...
|
CALL Option | 0.00% | 0.09% |
Sold All 😨
(Was: #84) |
0.3 | -157,600 | -100.0% |
CLOSED
|
— | $— | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTX
CONTEXT THERAPE...
|
Healthcare | 0.00% | 0.03% |
Sold All 😨
(Was: #90) |
0.3 | -402,653 | -100.0% |
CLOSED
|
— | $— | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RPTX
REPARE THERAPEU...
|
Healthcare | 0.00% | 0.03% |
Sold All 😨
(Was: #91) |
0.3 | -200,000 | -100.0% |
CLOSED
|
— | $— | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
N/A
CRESCENT BIOPHA...
|
—
|
Unknown | 0.00% | 0.02% |
Sold All 😨
(Was: #92) |
0.3 | -17,998 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | ||
|
SPRY
ARS PHARMACEUTI...
|
Healthcare | 0.00% | 0.00% |
Sold All 😨
(Was: #95) |
0.3 | -2,500 | -100.0% |
CLOSED
|
— | $— | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-25 of 125 holdings